TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Gender: men and women~2. Ethnicity: all ethnic groups~3. Age: ≥18, \< 75 years~4. Diagnosis of T2D -A1C within the last 90 days must be \>7.5%~5. Obesity, BMI ≥30~6. An Employee, or the significant other of an employee, that is covered by the Cleveland Clinic Employee Health Plan~Exclusion Criteria:~1. Type 1 diabetes or known latent autoimmune diabetes of adulthood (LADA)~2. Glomerular Filtration Rate \<30 mL/min/1.73 m2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration Equation, CKD-EPI)~3. Current glucocorticoid therapy~4. Currently or within the past 3 months receiving an anti-obesity medication, or any other medication used for the primary intent of weight loss~5. Any condition, unwillingness or inability, not covered by any of the other exclusion criteria, which, in the study clinician's opinion, might jeopardize the subject's safety or compliance with the protocol~6. Mental incapacity or language barrier~7. Pregnancy or plans to become pregnant within the next 2 years~8. Personal or family history of medullary thyroid carcinoma~9. Personal or family history of Multiple Endocrine Neoplasia syndrome type 2~10. History of acute pancreatitis, severe liver disease (Cirrhosis), or severe disease of digestive tract~11. History of congestive heart failure~12. History of bariatric or metabolic surgery/procedure~13. Visit with an endocrinologist within the past 1 year~14. Prior participation in the Endocrinology and Metabolism Institutes Integrated Weight Management Program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Obesity-centric approach + AOM (Type: EXPERIMENTAL): Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately two years. After discussing with the study doctor, participants will receive one of the following listed 4 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) phentermine/topiramate extended-release, 3) naltrexone/bupropion extended-release and 4) liraglutide 3.0 mg
- Obesity-centric approach without AOM (Type: EXPERIMENTAL): Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately two years.
- Usual care approach (Comorbidity-centric approach) (Type: ACTIVE_COMPARATOR): Participants will receive the traditional usual care/standard of care approach to T2D, hypertension, hypercholesterolemia management for approximately two years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females age 6 to 17 with a diagnosis of current depression with bipolar disorder based on clinical assessment and confirmed by structured diagnostic interview plus an initial Hamilton rating scale score \>17 and a Young Mania Rating Score of \< 15.~* Children will only be allowed to participate in the trial if they have had mood stabilization on a steady dose of medication for at least 2 months. By mood stabilization we mean as determined by principle investigator, evaluator clinician, and as confirmed by KSADS.~* Subject and parent must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.~* Subjects and their legal representative must be considered reliable.~* Each subject and his/her authorized legal representative must understand the nature of the study. The subject's authorized legal representative must sign an informed consent document and the subject must sign an informed assent document.~* Subject must be able to participate in mandatory blood draws.~* Subject must be able to swallow pills.~Exclusion Criteria:~Subjects with chronic medical illness, DSM-IV substance dependence within the past month, pregnant or nursing female subjects will be excluded from this study.~* Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild.~* Serious, unstable illness including hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrine, neurologic, immunologic, or hematologic disease.~* History of severe allergies or multiple adverse drug reactions.~* Non-febrile seizures without a clear and resolved etiology.~* Leukopenia or history of leukopenia without a clear and resolved etiology.~* Judged clinically to be at serious suicidal risk.~* Acute Psychosis~* Any other concomitant medication with primarily central nervous system activity other than specified in Concomitant Medication portion of the protocol.~* History of intolerance or non-response to bupropion.~* Treatment with nonreversible monoamine oxidase inhibitor within 2 weeks prior to initiation of study.~* Current diagnosis of schizophrenia.~* History of head trauma~* CNS tumor~* Diabetic treated with oral hypoglycemics or insulin~* Current or prior diagnosis of bulimia or anorexia

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prognosis and Therapeutic Biomarkers for Glioblastoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 22 years old~* Control Group (only patients evaluated for neurological disorders whose evaluation require a lumbar puncture)~* Non-Control Group - Diagnosed with GBM (Glioblastoma)~Exclusion Criteria:~* Pregnancy~* Infectious Disease to include cold, flu, HIV, etc.~* Blood Disorder (example:low platelets, anemia, thrombosis)~* Vascular Malformations

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: None): None
- Optune Only (Type: None): None
- Optune and TMZ (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with resectable pancreatic cancer.~2. Histologically confirmed and/or based on radiological imaging and laboratory tests confirmed pancreatic cancer by multidisciplinary team for pancreatic tumors.~3. Age more than 18.~4. Life expectancy more than 3 months.~5. Performance status - Karnofsky ≥ 70 or WHO \< or 2.~6. Treatment free interval 2-5 weeks, depending on the drugs used.~7. Patient must be mentally capable of understanding the information given.~8. Patient must give informed consent.~9. Patient must be discussed at the multidisciplinary team for pancreatic tumors before entering the trial.~Exclusion Criteria:~1. Secondary primary tumor, except surgically treated noninvasive cancer of cervix, or surgically or irradiated basal cell carcinoma.~2. Proven visceral, bone or diffuse metastases.~3. Life-threatening infection and/or heart failure and/or liver failure and/or renal failure (creatinine more than 150 µmol/L) other severe systemic pathologies.~4. Significant reduction in respiratory function.~5. Age less than 18 years.~6. Cumulative dose of 250 mg/m2 bleomycin received.~7. Allergic reaction to bleomycin.~8. Patients with epilepsy.~9. Patients with arrhythmias.~10. Patients with heart failure or pacemaker.~11. Pregnancy.~12. Patient incapable of understanding the aim of the study or disagree with the entering into the clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age.~2. Advanced solid tumor malignancies for whom no other therapy or intervention is available~3. Confirmation of measurable disease by RECIST v1.1~4. No uncontrolled hypertension, defined as \>140/90 mm Hg~5. A normal 12-lead ECG~6. At least two weeks since the last systemic anticancer therapy regimen prior to Cycle 1 Day 1; this includes radiation therapy.~7. ECOG performance status of 0-2.~8. Acceptable liver, renal and hematological function~9. Other protocol defined inclusion criteria may apply.~Exclusion Criteria~1. Has disease that is suitable for therapy administered with curative intent.~2. Ongoing treatment with another anticancer agent indicated for the malignancy for which the subject is enrolling into the study (excluding adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer).~3. History of cardiomyopathy, unstable angina within prior 6 months, myocardial infarction within prior 6 months, cerebrovascular attack within prior 6 months, history of New York Heart Association grade III or greater congestive heart failure, or current serious cardiac arrhythmia requiring medication.~4. Non-tolerable Grade 2 or ≥ Grade 3 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1.~5. Major surgery, other than diagnostic surgery, within 14 days prior to Cycle 1 Day 1, without complete recovery.~6. Active, uncontrolled bacterial, viral or fungal infections requiring systemic therapy.~7. Other protocol defined exclusion may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Group Assignment (Type: OTHER): Single Arm - Drug administered on Days 1-7 and Days 15-21 of a 28-day treatment cycle. Series of Pharmacokinetics and ECGs will be done during cycle 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Surgical Treatment for Rotator-Cuff Tears Using Platelet-Rich-Plasma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. subjects between ages 19 to 75, both male and female~2. radiologic imaging which can include either magnetic resonance imaging (MRI) or ultrasound (US) consistent with partial thickness rotator cuff tears of any degree except for full thickness tears~3. Failed a trial of physical therapy of at least 4 weeks~Exclusion Criteria:~1. Full thickness tears (well documented need for surgical correction)~2. sensory or neurologic complaint affecting the shoulder of interest~3. Coagulation disorder, platelet disorder~4. Pregnancy: Pregnancy test will be performed on women of childbearing age prior to their participation in the interventional portion of the study~5. Any major systemic illness such as ongoing infection or any condition that requires strict anti-platelet or anticoagulation therapy~6. Prior surgery to either cervical spine or shoulder~7. Active military~8. Injury part of worker compensation claim

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PRP injection into PTRCT (Type: ACTIVE_COMPARATOR): Treatment - PRP injection
- Subacromial steroid bursal injection (Type: ACTIVE_COMPARATOR): Current standard of care for treatment of resistant partial thickness rotator cuff tears

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Gabapentin, Ketamine and Dexamethasone on Pain and Opioid Requirements After Hip Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for primary total hip replacement,~* Between 55 and 85 years of age,~* ASA 1-3 and BMI between 18 and 35.~Exclusion Criteria:~Patients who are:~* Unable to cooperate~* Does not speak Danish~* Has allergy for drugs used in the trial~* Drug or alcohol abuse~* Epilepsy~* Medically treated diabetes~* Known kidney disease~* Daily use of analgetics~* Apart from NSAID~* Paracetamol or COX2 inhibitors~* Are treated with a antidepressive.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Males and females with ages between 18 and 65 years old, inclusive~* Except for obesity, otherwise healthy~* Body mass index (BMI) greater than or equal to 30.0 kg/m2 and less than or equal to 40.0 kg/m2 at screening~* Other Inclusion criteria may apply~Exclusion Criteria:~* Currently receiving treatment in another investigational device or drug study~* Women of childbearing potential~* History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion~* Other Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A (Type: EXPERIMENTAL): AMG 171 or placebo, 2 SAD cohorts
- Part B (Type: EXPERIMENTAL): AMG 171 or placebo, 1 MAD cohort
- Part C (Type: EXPERIMENTAL): AMG 171 or placebo, 3 titration cohorts

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years~* Continuous endotracheal ventilation~* Moderate - severe ARDS according to Berlin definition with PaO2/FiO2 ≤ 200 with PEEP \>= 5 cm H2O~* Date of ARDS onset : \>= day 5 and ≤ day 14 after the onset of ARDS criteria (regardless of ARDS severity)~* Procollagen III above 9 µg/L in a bronchoalveolar lavage performed by the attending physician between day 3 and day 13 after the onset of ARDS and realized within 5 days prior to randomization~Exclusion Criteria:~* Known pregnancy or breast feeding~* Participation to another interventional trial within 30 days with mortality or ventilator free days as the main endpoint~* Clinical evidence of active untreated infection~* A known, undrained abscess~* Intravascular nidus of infection~* Disseminated fungal infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone Group (Type: EXPERIMENTAL): Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive methylprednisolone
- Control Group (Type: PLACEBO_COMPARATOR): Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Positional Therapy to Treat Obstructive Sleep Apnea in Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute ischemic stroke~2. Patient has been treated at Sunnybrook Health Sciences Centre~Exclusion Criteria:~1. Patients who are unable to lie in a supine position (can be due to existing medical conditions)~2. Patients who are using positive airway pressure therapy or supplemental oxygen at the time of the study~3. Patients who are unable to use the portable sleep monitoring device~4. Physical impairment, aphasia, language barrier, facial/bulbar weakness or trauma restricting the ability to use the portable sleep monitor, and absence of caregiver who can provide assistance~5. Women who are pregnant during the study period

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Positional Therapy Belt (Type: EXPERIMENTAL): Use of positional therapy belt (SlumberBUMP) during sleep.
- Standard Care (Type: NO_INTERVENTION): No positional therapy belt provided for use during sleep.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has clinically or laboratory supported Multiple Sclerosis with evidence of INO by quantitative neurophysiologic criteria or has a history of ON.~2. Subject is between the ages of 18-65.~3. Subject is able to understand the demands of the protocol, has had any questions answered and has voluntarily signed the informed consent prior to any study procedures.~4. Subject has a peak saccadic acceleration ratio (abducting eye/adducting eye) of greater than 2S.D. above the mean derived form a normal control group.~5. Subject is otherwise in good health, based on complete medical history and physical examination, including vital signs and ECG.~Exclusion Criteria:~1. Subject is a pregnant female (as determined by a urine pregnancy test), a lactating female, or a female of child-bearing potential, not sterilized and not using one of the following methods of birth control: oral or injectable contraceptive agent, implantable contraceptive device, or barrier method.~2. Subject has a history of hypertension or diabetes.~3. Subject has known allergy to ACTH.~4. The subject has any medical condition, including psychiatric disease that might interfere with the interpretation of the results or with the conduct of the study.~5. Subject has a history of drug or ethanol abuse within the past year.~6. Subject has a history of ischemic heart disease.~7. Subject has received an investigational drug within 30 days of screening.~8. In opinion of investigator, subject is unlikely to complete study for any reason.~9. The subject has abnormal clinical laboratory values or an abnormal ECG, without approval of the study monitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ACTHAR- placebo first (Type: EXPERIMENTAL): Placebo, 20 mg, 40 mg, 80 mg
- ACTHAR- placebo second (Type: EXPERIMENTAL): 20mg, Placebo, 40 mg, 80mg
- ACTHAR- placebo third (Type: EXPERIMENTAL): 20 mg, 40 mg, Placebo, 80 mg
- ACTHAR- placebo fourth (Type: EXPERIMENTAL): 20 mg, 40 mg, 80 mg, Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues